Management of Non-Valvular Atrial Fibrillation – The New Era of Oral Anticoagulants
Muhib Khan, M.D., and Karen Furie, M.D., M.P.H.
Dr. Khan is Assistant Professor and Dr. Furie is Professor and Chair, Department of Neurology, The Warren Alpert Medical School of Brown University, and Neurologist-in-Chief, Rhode Island Hospital, The Miriam Hospital and Bradley Hospital, Providence, RI.
This Cyberounds® program was edited by Mark Crowther, M.D., M.Sc., Professor of Medicine, Pathology & Molecular Medicine and Clinical Epidemiology & Biostatistics, Associate Chair, Department of Medicine, Leo Pharma Chair in Thromboembolism, McMaster University School of Medicine, and Vice President, Research, St Joseph`s Healthcare System, Chief of Laboratory Medicine, Hamilton Health Sciences and St Joseph`s Healthcare, Toronto, Canada.
Within the past 12 months, Drs. Furie and Khan report no commercial conflicts of interest; Dr. Crowther has been on advisory boards for Leo Pharma, Pfizer, Bayer, Boehringer Ingelheim, Alexion, CSL Behring, Portola, Viropharm and AKP Americas, prepared educational materials/presentations for CSL Behring, Celgene, Pfizer and Octapharm, and his institution has received research grant support from Boehringer Ingelheim, Leo Pharma, Octapharm and Pfizer.
Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose.
This activity is certified for cardiovascular medicine, hematology, neurology, primary care (internal medicine, family practice and women’s health), physician assistants, nurse practitioners, nurses, pharmacists, and for all other health professionals interested in the management of atrial fibrillation stroke prevention.
This CME activity has been peer-reviewed by Ileana L. Piña, M.D., M.P.H., Professor of Medicine & Epidemiology and Population Health,
Albert Einstein College of Medicine, and Associate Chief for Academic Affairs, Division of Cardiology, Montefiore Medical Center, Bronx, New York.
This activity is made possible by an unrestricted educational grant from Boehringer Ingelheim
Estimated time to complete:
Albert Einstein College of Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Albert Einstein College of Medicine is accredited
by the Accreditation Council for Continuing
Medical Education to provide continuing medical
education for physicians.
Upon completion of this Cyberounds®
, you should be able to:
- Assess the thromboembolic risks associated with atrial fibrillation and apply this knowledge to patient stroke prevention
- Discuss the data emerging from recent clinical trials of prospective pharmacotherapies and strategies for atrial fibrillation stroke prevention including safety, efficacy and side effects
- Apply risk stratification in the selection of appropriate therapy (devices, surgeries and pharmacotherapies) for patients with atrial fibrillation.